vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Shoals Technologies Group, Inc. (SHLS). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $148.3M, roughly 1.2× Shoals Technologies Group, Inc.). Shoals Technologies Group, Inc. runs the higher net margin — 5.5% vs 1.6%, a 3.8% gap on every dollar of revenue. On growth, Shoals Technologies Group, Inc. posted the faster year-over-year revenue change (38.6% vs 5.0%). Over the past eight quarters, Shoals Technologies Group, Inc.'s revenue compounded faster (27.8% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Shoals Technologies Group is a leading provider of electrical balance of systems solutions for renewable energy and e-mobility. It supplies connectivity components for solar projects, energy storage systems and EV charging infrastructure, serving clients across North America, Europe and Asia-Pacific.
PCRX vs SHLS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $148.3M |
| Net Profit | $2.9M | $8.1M |
| Gross Margin | — | 31.6% |
| Operating Margin | 3.9% | 11.7% |
| Net Margin | 1.6% | 5.5% |
| Revenue YoY | 5.0% | 38.6% |
| Net Profit YoY | — | 3.9% |
| EPS (diluted) | $0.07 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $148.3M | ||
| Q3 25 | $179.5M | $135.8M | ||
| Q2 25 | $181.1M | $110.8M | ||
| Q1 25 | $168.9M | $80.4M | ||
| Q4 24 | $187.3M | $107.0M | ||
| Q3 24 | $168.6M | $102.2M | ||
| Q2 24 | $178.0M | $99.2M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $8.1M | ||
| Q3 25 | $5.4M | $11.9M | ||
| Q2 25 | $-4.8M | $13.9M | ||
| Q1 25 | $4.8M | $-282.0K | ||
| Q4 24 | — | $7.8M | ||
| Q3 24 | $-143.5M | $-267.0K | ||
| Q2 24 | $18.9M | $11.8M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 31.6% | ||
| Q3 25 | 80.9% | 37.0% | ||
| Q2 25 | 77.4% | 37.2% | ||
| Q1 25 | 79.7% | 35.0% | ||
| Q4 24 | 78.7% | 37.6% | ||
| Q3 24 | 76.9% | 24.8% | ||
| Q2 24 | 75.1% | 40.3% |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 11.7% | ||
| Q3 25 | 3.5% | 13.7% | ||
| Q2 25 | 4.7% | 14.4% | ||
| Q1 25 | 1.2% | 5.4% | ||
| Q4 24 | 13.2% | 15.4% | ||
| Q3 24 | -82.8% | 4.4% | ||
| Q2 24 | 15.9% | 18.7% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 5.5% | ||
| Q3 25 | 3.0% | 8.7% | ||
| Q2 25 | -2.7% | 12.5% | ||
| Q1 25 | 2.8% | -0.4% | ||
| Q4 24 | — | 7.3% | ||
| Q3 24 | -85.1% | -0.3% | ||
| Q2 24 | 10.6% | 11.9% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $0.05 | ||
| Q3 25 | $0.12 | $0.07 | ||
| Q2 25 | $-0.11 | $0.08 | ||
| Q1 25 | $0.10 | $0.00 | ||
| Q4 24 | $0.38 | $0.04 | ||
| Q3 24 | $-3.11 | $0.00 | ||
| Q2 24 | $0.39 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $7.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $600.0M |
| Total Assets | $1.2B | $904.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $7.3M | ||
| Q3 25 | $246.3M | $8.6M | ||
| Q2 25 | $445.9M | $4.7M | ||
| Q1 25 | $493.6M | $35.6M | ||
| Q4 24 | $484.6M | $23.5M | ||
| Q3 24 | $453.8M | $11.1M | ||
| Q2 24 | $404.2M | $3.2M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | $141.8M | ||
| Q4 24 | $585.3M | $141.8M | ||
| Q3 24 | — | $141.8M | ||
| Q2 24 | — | $146.8M |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $600.0M | ||
| Q3 25 | $727.2M | $589.6M | ||
| Q2 25 | $757.8M | $575.4M | ||
| Q1 25 | $798.5M | $558.9M | ||
| Q4 24 | $778.3M | $556.8M | ||
| Q3 24 | $749.6M | $545.2M | ||
| Q2 24 | $879.3M | $544.6M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $904.1M | ||
| Q3 25 | $1.3B | $851.8M | ||
| Q2 25 | $1.5B | $795.0M | ||
| Q1 25 | $1.6B | $788.4M | ||
| Q4 24 | $1.6B | $793.1M | ||
| Q3 24 | $1.5B | $801.3M | ||
| Q2 24 | $1.6B | $788.4M |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | 0.25× | ||
| Q4 24 | 0.75× | 0.25× | ||
| Q3 24 | — | 0.26× | ||
| Q2 24 | — | 0.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-4.1M |
| Free Cash FlowOCF − Capex | — | $-11.3M |
| FCF MarginFCF / Revenue | — | -7.6% |
| Capex IntensityCapex / Revenue | — | 4.8% |
| Cash ConversionOCF / Net Profit | — | -0.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-16.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $-4.1M | ||
| Q3 25 | $60.8M | $19.4M | ||
| Q2 25 | $12.0M | $-13.8M | ||
| Q1 25 | $35.5M | $15.6M | ||
| Q4 24 | $33.1M | $14.0M | ||
| Q3 24 | $53.9M | $15.7M | ||
| Q2 24 | $53.2M | $37.8M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $-11.3M | ||
| Q3 25 | $57.0M | $9.0M | ||
| Q2 25 | $9.3M | $-26.0M | ||
| Q1 25 | $26.9M | $12.3M | ||
| Q4 24 | $31.0M | $12.5M | ||
| Q3 24 | $49.8M | $13.3M | ||
| Q2 24 | $51.6M | $35.8M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | -7.6% | ||
| Q3 25 | 31.7% | 6.6% | ||
| Q2 25 | 5.1% | -23.5% | ||
| Q1 25 | 15.9% | 15.4% | ||
| Q4 24 | 16.6% | 11.6% | ||
| Q3 24 | 29.6% | 13.0% | ||
| Q2 24 | 29.0% | 36.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 4.8% | ||
| Q3 25 | 2.2% | 7.7% | ||
| Q2 25 | 1.5% | 11.0% | ||
| Q1 25 | 5.1% | 4.0% | ||
| Q4 24 | 1.1% | 1.4% | ||
| Q3 24 | 2.4% | 2.3% | ||
| Q2 24 | 0.9% | 2.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | -0.50× | ||
| Q3 25 | 11.20× | 1.63× | ||
| Q2 25 | — | -1.00× | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | 3.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
SHLS
| System Solutions | $122.0M | 82% |
| Components | $26.3M | 18% |
